Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Net Margin (2020 - 2026)

GeneDx Holdings has reported Net Margin over the past 7 years, most recently at 61.92% for Q1 2026.

  • Quarterly Net Margin fell 5448.0% to 61.92% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 17.58% through Mar 2026, down 591.0% year-over-year, with the annual reading at 4.92% for FY2025, 1220.0% up from the prior year.
  • Net Margin was 61.92% for Q1 2026 at GeneDx Holdings, down from 14.64% in the prior quarter.
  • Over five years, Net Margin peaked at 10.53% in Q2 2025 and troughed at 503.21% in Q4 2022.
  • The 5-year median for Net Margin is 44.86% (2023), against an average of 88.02%.
  • Year-over-year, Net Margin tumbled -43369bps in 2022 and then surged 45835bps in 2023.
  • A 5-year view of Net Margin shows it stood at 503.21% in 2022, then soared by 91bps to 44.86% in 2023, then surged by 113bps to 5.69% in 2024, then plummeted by -357bps to 14.64% in 2025, then crashed by -323bps to 61.92% in 2026.
  • Per Business Quant, the three most recent readings for WGS's Net Margin are 61.92% (Q1 2026), 14.64% (Q4 2025), and 6.5% (Q3 2025).